Cell Discovery-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2180511, encodeId=72062180511bb, content=请问学界对这篇杂志的口碑到底如何？会不会影响申请基金？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1d96302450, createdName=3783633_3040, createdTime=Wed Jan 10 15:23:06 CST 2024, time=2024-01-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=570206, encodeId=160c5e0206ee, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：看好这个杂志，投了一篇，Cell research拒了建议转的这个，一审1个月，3个审稿人，意见正面，补少量实验1个月后修回，二审少数语言问题，一星期休回，然后accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f8a32141202, createdName=05482, createdTime=Mon Apr 29 00:00:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576357, encodeId=3f5f5e6357e0, content=今年可能6到7分spanclassquote174978320190429发表br接收率约50审稿时间约1个月看好这个杂志投了一篇Cellresearch拒了建议转的这个一审1个月3个审稿人意见正面补少量实验1个月后修回二审少数语言问题一星期休回然后acceptspan, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=264, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2311682109, createdName=加州理工的工人, createdTime=Sun Sep 15 19:42:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222074, encodeId=582e12220e4a4, content=请问大家，像类似的这种期刊，每期三篇研究论文，其余的要么综述，要么就是莱特儿，能投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0e5b5549664, createdName=ms7000000308199462, createdTime=Tue May 24 13:20:09 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231253, encodeId=678c123125394, content=可以有几位共一？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cacb8111229, createdName=ms4000000787672752, createdTime=Fri Jul 08 06:55:43 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214036, encodeId=cb95121403633, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：今年6月IF即将突破35分，现在已经非常难投了。cr已经起势自不必说，cd现在的作者质量也极高，院士杰青优青作通讯的文章甚至占了1/3以上。趋势很明显，两个杂志主编都是李，他要把中科院旗下双子星cell research和cell discovery打造成国内第一和第二的国产杂志。质量上会明显超过sttt，prorein cell之流。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/18/56186736f4d1be1601744995196f2ab0.jpg, createdBy=a3d41955761, createdName=dgdgdgygygyg, createdTime=Mon Apr 25 08:17:55 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107471, encodeId=3420110e47156, content=所有作者在文章接收之后都会接收到邮件吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Wed Dec 29 14:52:53 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107472, encodeId=ff13110e47249, content=同一杂志社不同期刊如何转投（transfer）？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Wed Dec 29 14:52:53 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2189973, encodeId=234021899e304, content=偏重的研究方向：免疫、单细胞测序 经验分享：已经投稿21天了还是under consideration状态，这是还在editor那里嘛...不是说这个杂志稿件处理很快嘛...忐忑..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ce55107049, createdName=146080dfm79(暂无昵称), createdTime=Wed Feb 28 21:26:55 CST 2024, time=2024-02-28, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2170492, encodeId=db6921e0492ae, content=杂志口碑一般，有好的科研成果建议投其他子刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf8a8233627, createdName=ms8000001941475625, createdTime=Thu Nov 23 11:49:13 CST 2023, time=2023-11-23, status=1, ipAttribution=江苏省)]

2024-01-10 3783633_3040 来自安徽省

请问学界对这篇杂志的口碑到底如何？会不会影响申请基金？

35 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2180511, encodeId=72062180511bb, content=请问学界对这篇杂志的口碑到底如何？会不会影响申请基金？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1d96302450, createdName=3783633_3040, createdTime=Wed Jan 10 15:23:06 CST 2024, time=2024-01-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=570206, encodeId=160c5e0206ee, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：看好这个杂志，投了一篇，Cell research拒了建议转的这个，一审1个月，3个审稿人，意见正面，补少量实验1个月后修回，二审少数语言问题，一星期休回，然后accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f8a32141202, createdName=05482, createdTime=Mon Apr 29 00:00:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576357, encodeId=3f5f5e6357e0, content=今年可能6到7分spanclassquote174978320190429发表br接收率约50审稿时间约1个月看好这个杂志投了一篇Cellresearch拒了建议转的这个一审1个月3个审稿人意见正面补少量实验1个月后修回二审少数语言问题一星期休回然后acceptspan, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=264, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2311682109, createdName=加州理工的工人, createdTime=Sun Sep 15 19:42:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222074, encodeId=582e12220e4a4, content=请问大家，像类似的这种期刊，每期三篇研究论文，其余的要么综述，要么就是莱特儿，能投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0e5b5549664, createdName=ms7000000308199462, createdTime=Tue May 24 13:20:09 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231253, encodeId=678c123125394, content=可以有几位共一？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cacb8111229, createdName=ms4000000787672752, createdTime=Fri Jul 08 06:55:43 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214036, encodeId=cb95121403633, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：今年6月IF即将突破35分，现在已经非常难投了。cr已经起势自不必说，cd现在的作者质量也极高，院士杰青优青作通讯的文章甚至占了1/3以上。趋势很明显，两个杂志主编都是李，他要把中科院旗下双子星cell research和cell discovery打造成国内第一和第二的国产杂志。质量上会明显超过sttt，prorein cell之流。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/18/56186736f4d1be1601744995196f2ab0.jpg, createdBy=a3d41955761, createdName=dgdgdgygygyg, createdTime=Mon Apr 25 08:17:55 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107471, encodeId=3420110e47156, content=所有作者在文章接收之后都会接收到邮件吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Wed Dec 29 14:52:53 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107472, encodeId=ff13110e47249, content=同一杂志社不同期刊如何转投（transfer）？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Wed Dec 29 14:52:53 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2189973, encodeId=234021899e304, content=偏重的研究方向：免疫、单细胞测序 经验分享：已经投稿21天了还是under consideration状态，这是还在editor那里嘛...不是说这个杂志稿件处理很快嘛...忐忑..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ce55107049, createdName=146080dfm79(暂无昵称), createdTime=Wed Feb 28 21:26:55 CST 2024, time=2024-02-28, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2170492, encodeId=db6921e0492ae, content=杂志口碑一般，有好的科研成果建议投其他子刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf8a8233627, createdName=ms8000001941475625, createdTime=Thu Nov 23 11:49:13 CST 2023, time=2023-11-23, status=1, ipAttribution=江苏省)]

2019-04-29 05482

审稿速度:1.0 | 投稿命中率:50.0
经验分享：看好这个杂志，投了一篇，Cell research拒了建议转的这个，一审1个月，3个审稿人，意见正面，补少量实验1个月后修回，二审少数语言问题，一星期休回，然后accept

288 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2180511, encodeId=72062180511bb, content=请问学界对这篇杂志的口碑到底如何？会不会影响申请基金？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1d96302450, createdName=3783633_3040, createdTime=Wed Jan 10 15:23:06 CST 2024, time=2024-01-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=570206, encodeId=160c5e0206ee, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：看好这个杂志，投了一篇，Cell research拒了建议转的这个，一审1个月，3个审稿人，意见正面，补少量实验1个月后修回，二审少数语言问题，一星期休回，然后accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f8a32141202, createdName=05482, createdTime=Mon Apr 29 00:00:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576357, encodeId=3f5f5e6357e0, content=今年可能6到7分spanclassquote174978320190429发表br接收率约50审稿时间约1个月看好这个杂志投了一篇Cellresearch拒了建议转的这个一审1个月3个审稿人意见正面补少量实验1个月后修回二审少数语言问题一星期休回然后acceptspan, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=264, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2311682109, createdName=加州理工的工人, createdTime=Sun Sep 15 19:42:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222074, encodeId=582e12220e4a4, content=请问大家，像类似的这种期刊，每期三篇研究论文，其余的要么综述，要么就是莱特儿，能投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0e5b5549664, createdName=ms7000000308199462, createdTime=Tue May 24 13:20:09 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231253, encodeId=678c123125394, content=可以有几位共一？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cacb8111229, createdName=ms4000000787672752, createdTime=Fri Jul 08 06:55:43 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214036, encodeId=cb95121403633, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：今年6月IF即将突破35分，现在已经非常难投了。cr已经起势自不必说，cd现在的作者质量也极高，院士杰青优青作通讯的文章甚至占了1/3以上。趋势很明显，两个杂志主编都是李，他要把中科院旗下双子星cell research和cell discovery打造成国内第一和第二的国产杂志。质量上会明显超过sttt，prorein cell之流。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/18/56186736f4d1be1601744995196f2ab0.jpg, createdBy=a3d41955761, createdName=dgdgdgygygyg, createdTime=Mon Apr 25 08:17:55 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107471, encodeId=3420110e47156, content=所有作者在文章接收之后都会接收到邮件吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Wed Dec 29 14:52:53 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107472, encodeId=ff13110e47249, content=同一杂志社不同期刊如何转投（transfer）？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Wed Dec 29 14:52:53 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2189973, encodeId=234021899e304, content=偏重的研究方向：免疫、单细胞测序 经验分享：已经投稿21天了还是under consideration状态，这是还在editor那里嘛...不是说这个杂志稿件处理很快嘛...忐忑..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ce55107049, createdName=146080dfm79(暂无昵称), createdTime=Wed Feb 28 21:26:55 CST 2024, time=2024-02-28, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2170492, encodeId=db6921e0492ae, content=杂志口碑一般，有好的科研成果建议投其他子刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf8a8233627, createdName=ms8000001941475625, createdTime=Thu Nov 23 11:49:13 CST 2023, time=2023-11-23, status=1, ipAttribution=江苏省)]

2019-09-15 加州理工的工人

今年可能6到7分spanclassquote174978320190429发表br接收率约50审稿时间约1个月看好这个杂志投了一篇Cellresearch拒了建议转的这个一审1个月3个审稿人意见正面补少量实验1个月后修回二审少数语言问题一星期休回然后acceptspan

264 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2180511, encodeId=72062180511bb, content=请问学界对这篇杂志的口碑到底如何？会不会影响申请基金？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1d96302450, createdName=3783633_3040, createdTime=Wed Jan 10 15:23:06 CST 2024, time=2024-01-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=570206, encodeId=160c5e0206ee, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：看好这个杂志，投了一篇，Cell research拒了建议转的这个，一审1个月，3个审稿人，意见正面，补少量实验1个月后修回，二审少数语言问题，一星期休回，然后accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f8a32141202, createdName=05482, createdTime=Mon Apr 29 00:00:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576357, encodeId=3f5f5e6357e0, content=今年可能6到7分spanclassquote174978320190429发表br接收率约50审稿时间约1个月看好这个杂志投了一篇Cellresearch拒了建议转的这个一审1个月3个审稿人意见正面补少量实验1个月后修回二审少数语言问题一星期休回然后acceptspan, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=264, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2311682109, createdName=加州理工的工人, createdTime=Sun Sep 15 19:42:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222074, encodeId=582e12220e4a4, content=请问大家，像类似的这种期刊，每期三篇研究论文，其余的要么综述，要么就是莱特儿，能投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0e5b5549664, createdName=ms7000000308199462, createdTime=Tue May 24 13:20:09 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231253, encodeId=678c123125394, content=可以有几位共一？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cacb8111229, createdName=ms4000000787672752, createdTime=Fri Jul 08 06:55:43 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214036, encodeId=cb95121403633, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：今年6月IF即将突破35分，现在已经非常难投了。cr已经起势自不必说，cd现在的作者质量也极高，院士杰青优青作通讯的文章甚至占了1/3以上。趋势很明显，两个杂志主编都是李，他要把中科院旗下双子星cell research和cell discovery打造成国内第一和第二的国产杂志。质量上会明显超过sttt，prorein cell之流。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/18/56186736f4d1be1601744995196f2ab0.jpg, createdBy=a3d41955761, createdName=dgdgdgygygyg, createdTime=Mon Apr 25 08:17:55 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107471, encodeId=3420110e47156, content=所有作者在文章接收之后都会接收到邮件吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Wed Dec 29 14:52:53 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107472, encodeId=ff13110e47249, content=同一杂志社不同期刊如何转投（transfer）？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Wed Dec 29 14:52:53 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2189973, encodeId=234021899e304, content=偏重的研究方向：免疫、单细胞测序 经验分享：已经投稿21天了还是under consideration状态，这是还在editor那里嘛...不是说这个杂志稿件处理很快嘛...忐忑..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ce55107049, createdName=146080dfm79(暂无昵称), createdTime=Wed Feb 28 21:26:55 CST 2024, time=2024-02-28, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2170492, encodeId=db6921e0492ae, content=杂志口碑一般，有好的科研成果建议投其他子刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf8a8233627, createdName=ms8000001941475625, createdTime=Thu Nov 23 11:49:13 CST 2023, time=2023-11-23, status=1, ipAttribution=江苏省)]

2022-05-24 ms7000000308199462

请问大家，像类似的这种期刊，每期三篇研究论文，其余的要么综述，要么就是莱特儿，能投吗？

182 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2180511, encodeId=72062180511bb, content=请问学界对这篇杂志的口碑到底如何？会不会影响申请基金？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1d96302450, createdName=3783633_3040, createdTime=Wed Jan 10 15:23:06 CST 2024, time=2024-01-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=570206, encodeId=160c5e0206ee, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：看好这个杂志，投了一篇，Cell research拒了建议转的这个，一审1个月，3个审稿人，意见正面，补少量实验1个月后修回，二审少数语言问题，一星期休回，然后accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f8a32141202, createdName=05482, createdTime=Mon Apr 29 00:00:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576357, encodeId=3f5f5e6357e0, content=今年可能6到7分spanclassquote174978320190429发表br接收率约50审稿时间约1个月看好这个杂志投了一篇Cellresearch拒了建议转的这个一审1个月3个审稿人意见正面补少量实验1个月后修回二审少数语言问题一星期休回然后acceptspan, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=264, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2311682109, createdName=加州理工的工人, createdTime=Sun Sep 15 19:42:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222074, encodeId=582e12220e4a4, content=请问大家，像类似的这种期刊，每期三篇研究论文，其余的要么综述，要么就是莱特儿，能投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0e5b5549664, createdName=ms7000000308199462, createdTime=Tue May 24 13:20:09 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231253, encodeId=678c123125394, content=可以有几位共一？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cacb8111229, createdName=ms4000000787672752, createdTime=Fri Jul 08 06:55:43 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214036, encodeId=cb95121403633, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：今年6月IF即将突破35分，现在已经非常难投了。cr已经起势自不必说，cd现在的作者质量也极高，院士杰青优青作通讯的文章甚至占了1/3以上。趋势很明显，两个杂志主编都是李，他要把中科院旗下双子星cell research和cell discovery打造成国内第一和第二的国产杂志。质量上会明显超过sttt，prorein cell之流。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/18/56186736f4d1be1601744995196f2ab0.jpg, createdBy=a3d41955761, createdName=dgdgdgygygyg, createdTime=Mon Apr 25 08:17:55 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107471, encodeId=3420110e47156, content=所有作者在文章接收之后都会接收到邮件吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Wed Dec 29 14:52:53 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107472, encodeId=ff13110e47249, content=同一杂志社不同期刊如何转投（transfer）？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Wed Dec 29 14:52:53 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2189973, encodeId=234021899e304, content=偏重的研究方向：免疫、单细胞测序 经验分享：已经投稿21天了还是under consideration状态，这是还在editor那里嘛...不是说这个杂志稿件处理很快嘛...忐忑..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ce55107049, createdName=146080dfm79(暂无昵称), createdTime=Wed Feb 28 21:26:55 CST 2024, time=2024-02-28, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2170492, encodeId=db6921e0492ae, content=杂志口碑一般，有好的科研成果建议投其他子刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf8a8233627, createdName=ms8000001941475625, createdTime=Thu Nov 23 11:49:13 CST 2023, time=2023-11-23, status=1, ipAttribution=江苏省)]

2022-07-08 ms4000000787672752

可以有几位共一？

133 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2180511, encodeId=72062180511bb, content=请问学界对这篇杂志的口碑到底如何？会不会影响申请基金？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1d96302450, createdName=3783633_3040, createdTime=Wed Jan 10 15:23:06 CST 2024, time=2024-01-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=570206, encodeId=160c5e0206ee, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：看好这个杂志，投了一篇，Cell research拒了建议转的这个，一审1个月，3个审稿人，意见正面，补少量实验1个月后修回，二审少数语言问题，一星期休回，然后accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f8a32141202, createdName=05482, createdTime=Mon Apr 29 00:00:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576357, encodeId=3f5f5e6357e0, content=今年可能6到7分spanclassquote174978320190429发表br接收率约50审稿时间约1个月看好这个杂志投了一篇Cellresearch拒了建议转的这个一审1个月3个审稿人意见正面补少量实验1个月后修回二审少数语言问题一星期休回然后acceptspan, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=264, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2311682109, createdName=加州理工的工人, createdTime=Sun Sep 15 19:42:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222074, encodeId=582e12220e4a4, content=请问大家，像类似的这种期刊，每期三篇研究论文，其余的要么综述，要么就是莱特儿，能投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0e5b5549664, createdName=ms7000000308199462, createdTime=Tue May 24 13:20:09 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231253, encodeId=678c123125394, content=可以有几位共一？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cacb8111229, createdName=ms4000000787672752, createdTime=Fri Jul 08 06:55:43 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214036, encodeId=cb95121403633, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：今年6月IF即将突破35分，现在已经非常难投了。cr已经起势自不必说，cd现在的作者质量也极高，院士杰青优青作通讯的文章甚至占了1/3以上。趋势很明显，两个杂志主编都是李，他要把中科院旗下双子星cell research和cell discovery打造成国内第一和第二的国产杂志。质量上会明显超过sttt，prorein cell之流。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/18/56186736f4d1be1601744995196f2ab0.jpg, createdBy=a3d41955761, createdName=dgdgdgygygyg, createdTime=Mon Apr 25 08:17:55 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107471, encodeId=3420110e47156, content=所有作者在文章接收之后都会接收到邮件吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Wed Dec 29 14:52:53 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107472, encodeId=ff13110e47249, content=同一杂志社不同期刊如何转投（transfer）？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Wed Dec 29 14:52:53 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2189973, encodeId=234021899e304, content=偏重的研究方向：免疫、单细胞测序 经验分享：已经投稿21天了还是under consideration状态，这是还在editor那里嘛...不是说这个杂志稿件处理很快嘛...忐忑..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ce55107049, createdName=146080dfm79(暂无昵称), createdTime=Wed Feb 28 21:26:55 CST 2024, time=2024-02-28, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2170492, encodeId=db6921e0492ae, content=杂志口碑一般，有好的科研成果建议投其他子刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf8a8233627, createdName=ms8000001941475625, createdTime=Thu Nov 23 11:49:13 CST 2023, time=2023-11-23, status=1, ipAttribution=江苏省)]

2022-04-25 dgdgdgygygyg

审稿速度:2.0 | 投稿命中率:25.0
经验分享：今年6月IF即将突破35分，现在已经非常难投了。cr已经起势自不必说，cd现在的作者质量也极高，院士杰青优青作通讯的文章甚至占了1/3以上。趋势很明显，两个杂志主编都是李，他要把中科院旗下双子星cell research和cell discovery打造成国内第一和第二的国产杂志。质量上会明显超过sttt，prorein cell之流。

153 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2180511, encodeId=72062180511bb, content=请问学界对这篇杂志的口碑到底如何？会不会影响申请基金？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1d96302450, createdName=3783633_3040, createdTime=Wed Jan 10 15:23:06 CST 2024, time=2024-01-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=570206, encodeId=160c5e0206ee, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：看好这个杂志，投了一篇，Cell research拒了建议转的这个，一审1个月，3个审稿人，意见正面，补少量实验1个月后修回，二审少数语言问题，一星期休回，然后accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f8a32141202, createdName=05482, createdTime=Mon Apr 29 00:00:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576357, encodeId=3f5f5e6357e0, content=今年可能6到7分spanclassquote174978320190429发表br接收率约50审稿时间约1个月看好这个杂志投了一篇Cellresearch拒了建议转的这个一审1个月3个审稿人意见正面补少量实验1个月后修回二审少数语言问题一星期休回然后acceptspan, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=264, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2311682109, createdName=加州理工的工人, createdTime=Sun Sep 15 19:42:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222074, encodeId=582e12220e4a4, content=请问大家，像类似的这种期刊，每期三篇研究论文，其余的要么综述，要么就是莱特儿，能投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0e5b5549664, createdName=ms7000000308199462, createdTime=Tue May 24 13:20:09 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231253, encodeId=678c123125394, content=可以有几位共一？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cacb8111229, createdName=ms4000000787672752, createdTime=Fri Jul 08 06:55:43 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214036, encodeId=cb95121403633, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：今年6月IF即将突破35分，现在已经非常难投了。cr已经起势自不必说，cd现在的作者质量也极高，院士杰青优青作通讯的文章甚至占了1/3以上。趋势很明显，两个杂志主编都是李，他要把中科院旗下双子星cell research和cell discovery打造成国内第一和第二的国产杂志。质量上会明显超过sttt，prorein cell之流。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/18/56186736f4d1be1601744995196f2ab0.jpg, createdBy=a3d41955761, createdName=dgdgdgygygyg, createdTime=Mon Apr 25 08:17:55 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107471, encodeId=3420110e47156, content=所有作者在文章接收之后都会接收到邮件吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Wed Dec 29 14:52:53 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107472, encodeId=ff13110e47249, content=同一杂志社不同期刊如何转投（transfer）？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Wed Dec 29 14:52:53 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2189973, encodeId=234021899e304, content=偏重的研究方向：免疫、单细胞测序 经验分享：已经投稿21天了还是under consideration状态，这是还在editor那里嘛...不是说这个杂志稿件处理很快嘛...忐忑..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ce55107049, createdName=146080dfm79(暂无昵称), createdTime=Wed Feb 28 21:26:55 CST 2024, time=2024-02-28, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2170492, encodeId=db6921e0492ae, content=杂志口碑一般，有好的科研成果建议投其他子刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf8a8233627, createdName=ms8000001941475625, createdTime=Thu Nov 23 11:49:13 CST 2023, time=2023-11-23, status=1, ipAttribution=江苏省)]

2021-12-29 乌云背后的幸福线

所有作者在文章接收之后都会接收到邮件吗？

82 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2180511, encodeId=72062180511bb, content=请问学界对这篇杂志的口碑到底如何？会不会影响申请基金？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1d96302450, createdName=3783633_3040, createdTime=Wed Jan 10 15:23:06 CST 2024, time=2024-01-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=570206, encodeId=160c5e0206ee, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：看好这个杂志，投了一篇，Cell research拒了建议转的这个，一审1个月，3个审稿人，意见正面，补少量实验1个月后修回，二审少数语言问题，一星期休回，然后accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f8a32141202, createdName=05482, createdTime=Mon Apr 29 00:00:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576357, encodeId=3f5f5e6357e0, content=今年可能6到7分spanclassquote174978320190429发表br接收率约50审稿时间约1个月看好这个杂志投了一篇Cellresearch拒了建议转的这个一审1个月3个审稿人意见正面补少量实验1个月后修回二审少数语言问题一星期休回然后acceptspan, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=264, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2311682109, createdName=加州理工的工人, createdTime=Sun Sep 15 19:42:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222074, encodeId=582e12220e4a4, content=请问大家，像类似的这种期刊，每期三篇研究论文，其余的要么综述，要么就是莱特儿，能投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0e5b5549664, createdName=ms7000000308199462, createdTime=Tue May 24 13:20:09 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231253, encodeId=678c123125394, content=可以有几位共一？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cacb8111229, createdName=ms4000000787672752, createdTime=Fri Jul 08 06:55:43 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214036, encodeId=cb95121403633, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：今年6月IF即将突破35分，现在已经非常难投了。cr已经起势自不必说，cd现在的作者质量也极高，院士杰青优青作通讯的文章甚至占了1/3以上。趋势很明显，两个杂志主编都是李，他要把中科院旗下双子星cell research和cell discovery打造成国内第一和第二的国产杂志。质量上会明显超过sttt，prorein cell之流。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/18/56186736f4d1be1601744995196f2ab0.jpg, createdBy=a3d41955761, createdName=dgdgdgygygyg, createdTime=Mon Apr 25 08:17:55 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107471, encodeId=3420110e47156, content=所有作者在文章接收之后都会接收到邮件吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Wed Dec 29 14:52:53 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107472, encodeId=ff13110e47249, content=同一杂志社不同期刊如何转投（transfer）？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Wed Dec 29 14:52:53 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2189973, encodeId=234021899e304, content=偏重的研究方向：免疫、单细胞测序 经验分享：已经投稿21天了还是under consideration状态，这是还在editor那里嘛...不是说这个杂志稿件处理很快嘛...忐忑..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ce55107049, createdName=146080dfm79(暂无昵称), createdTime=Wed Feb 28 21:26:55 CST 2024, time=2024-02-28, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2170492, encodeId=db6921e0492ae, content=杂志口碑一般，有好的科研成果建议投其他子刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf8a8233627, createdName=ms8000001941475625, createdTime=Thu Nov 23 11:49:13 CST 2023, time=2023-11-23, status=1, ipAttribution=江苏省)]

2021-12-29 rayms

同一杂志社不同期刊如何转投（transfer）？

87 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2180511, encodeId=72062180511bb, content=请问学界对这篇杂志的口碑到底如何？会不会影响申请基金？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1d96302450, createdName=3783633_3040, createdTime=Wed Jan 10 15:23:06 CST 2024, time=2024-01-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=570206, encodeId=160c5e0206ee, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：看好这个杂志，投了一篇，Cell research拒了建议转的这个，一审1个月，3个审稿人，意见正面，补少量实验1个月后修回，二审少数语言问题，一星期休回，然后accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f8a32141202, createdName=05482, createdTime=Mon Apr 29 00:00:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576357, encodeId=3f5f5e6357e0, content=今年可能6到7分spanclassquote174978320190429发表br接收率约50审稿时间约1个月看好这个杂志投了一篇Cellresearch拒了建议转的这个一审1个月3个审稿人意见正面补少量实验1个月后修回二审少数语言问题一星期休回然后acceptspan, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=264, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2311682109, createdName=加州理工的工人, createdTime=Sun Sep 15 19:42:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222074, encodeId=582e12220e4a4, content=请问大家，像类似的这种期刊，每期三篇研究论文，其余的要么综述，要么就是莱特儿，能投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0e5b5549664, createdName=ms7000000308199462, createdTime=Tue May 24 13:20:09 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231253, encodeId=678c123125394, content=可以有几位共一？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cacb8111229, createdName=ms4000000787672752, createdTime=Fri Jul 08 06:55:43 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214036, encodeId=cb95121403633, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：今年6月IF即将突破35分，现在已经非常难投了。cr已经起势自不必说，cd现在的作者质量也极高，院士杰青优青作通讯的文章甚至占了1/3以上。趋势很明显，两个杂志主编都是李，他要把中科院旗下双子星cell research和cell discovery打造成国内第一和第二的国产杂志。质量上会明显超过sttt，prorein cell之流。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/18/56186736f4d1be1601744995196f2ab0.jpg, createdBy=a3d41955761, createdName=dgdgdgygygyg, createdTime=Mon Apr 25 08:17:55 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107471, encodeId=3420110e47156, content=所有作者在文章接收之后都会接收到邮件吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Wed Dec 29 14:52:53 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107472, encodeId=ff13110e47249, content=同一杂志社不同期刊如何转投（transfer）？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Wed Dec 29 14:52:53 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2189973, encodeId=234021899e304, content=偏重的研究方向：免疫、单细胞测序 经验分享：已经投稿21天了还是under consideration状态，这是还在editor那里嘛...不是说这个杂志稿件处理很快嘛...忐忑..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ce55107049, createdName=146080dfm79(暂无昵称), createdTime=Wed Feb 28 21:26:55 CST 2024, time=2024-02-28, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2170492, encodeId=db6921e0492ae, content=杂志口碑一般，有好的科研成果建议投其他子刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf8a8233627, createdName=ms8000001941475625, createdTime=Thu Nov 23 11:49:13 CST 2023, time=2023-11-23, status=1, ipAttribution=江苏省)]

2024-02-28 146080dfm79(暂无昵称) 来自北京

偏重的研究方向：免疫、单细胞测序
经验分享：已经投稿21天了还是under consideration状态，这是还在editor那里嘛...不是说这个杂志稿件处理很快嘛...忐忑...

26 0

[GetPortalCommentsPageByObjectIdResponse(id=2180511, encodeId=72062180511bb, content=请问学界对这篇杂志的口碑到底如何？会不会影响申请基金？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1d96302450, createdName=3783633_3040, createdTime=Wed Jan 10 15:23:06 CST 2024, time=2024-01-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=570206, encodeId=160c5e0206ee, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：看好这个杂志，投了一篇，Cell research拒了建议转的这个，一审1个月，3个审稿人，意见正面，补少量实验1个月后修回，二审少数语言问题，一星期休回，然后accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f8a32141202, createdName=05482, createdTime=Mon Apr 29 00:00:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576357, encodeId=3f5f5e6357e0, content=今年可能6到7分spanclassquote174978320190429发表br接收率约50审稿时间约1个月看好这个杂志投了一篇Cellresearch拒了建议转的这个一审1个月3个审稿人意见正面补少量实验1个月后修回二审少数语言问题一星期休回然后acceptspan, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=264, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2311682109, createdName=加州理工的工人, createdTime=Sun Sep 15 19:42:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222074, encodeId=582e12220e4a4, content=请问大家，像类似的这种期刊，每期三篇研究论文，其余的要么综述，要么就是莱特儿，能投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0e5b5549664, createdName=ms7000000308199462, createdTime=Tue May 24 13:20:09 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231253, encodeId=678c123125394, content=可以有几位共一？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cacb8111229, createdName=ms4000000787672752, createdTime=Fri Jul 08 06:55:43 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214036, encodeId=cb95121403633, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：今年6月IF即将突破35分，现在已经非常难投了。cr已经起势自不必说，cd现在的作者质量也极高，院士杰青优青作通讯的文章甚至占了1/3以上。趋势很明显，两个杂志主编都是李，他要把中科院旗下双子星cell research和cell discovery打造成国内第一和第二的国产杂志。质量上会明显超过sttt，prorein cell之流。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/18/56186736f4d1be1601744995196f2ab0.jpg, createdBy=a3d41955761, createdName=dgdgdgygygyg, createdTime=Mon Apr 25 08:17:55 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107471, encodeId=3420110e47156, content=所有作者在文章接收之后都会接收到邮件吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Wed Dec 29 14:52:53 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107472, encodeId=ff13110e47249, content=同一杂志社不同期刊如何转投（transfer）？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Wed Dec 29 14:52:53 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2189973, encodeId=234021899e304, content=偏重的研究方向：免疫、单细胞测序 经验分享：已经投稿21天了还是under consideration状态，这是还在editor那里嘛...不是说这个杂志稿件处理很快嘛...忐忑..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ce55107049, createdName=146080dfm79(暂无昵称), createdTime=Wed Feb 28 21:26:55 CST 2024, time=2024-02-28, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2170492, encodeId=db6921e0492ae, content=杂志口碑一般，有好的科研成果建议投其他子刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf8a8233627, createdName=ms8000001941475625, createdTime=Thu Nov 23 11:49:13 CST 2023, time=2023-11-23, status=1, ipAttribution=江苏省)]

2023-11-23 ms8000001941475625 来自江苏省

杂志口碑一般，有好的科研成果建议投其他子刊

52 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务